Successfully delivering, phase I to phase III, full service global clinical trials
Early Access Programs
Our Early Access Programs deliver potentially lifesaving treatments to patients around the world
We provide a unique, combined approach to Clinical Development, Early Access Programs and Clinical Trial Supply. Our expert teams work seamlessly across our divisions, where they continuously use their experience and knowledge to plan, develop and execute projects to exceptionally high standards.
We build long-term, mutually beneficial partnerships. We listen carefully to what you tell us and share our insight to enhance results and deliver success. We are innovative but realistic in our recommendations, meeting your objectives while staying true to your culture.
At Bionical Emas, we like to keep our clients up-to-date with relevant news and key market insight.
G1 Therapeutics, Inc and Bionical Emas Launch Expanded Access Program for Trilaciclib in Small Cell Lung Cancer in the United States
Four things to think about: PVG in EAPs
By Nisha Vora - Senior Project Manager, Pharmacovigilance
Nuances in Pharmacovigilance case processing in Early Access Programs
By Harry Woods - Pharmacovigilance Associate
What does Early Access actually mean?
Naomi Litchfield, Patient Advocacy Manager for Bionical Emas, discusses the basic principles of Early Access Programs